Mark Tracy

Mark Tracy is a highly accomplished biopharmaceutical product development executive with 20 years of experience in scientific, managerial, business, and alliance leadership roles.

His expertise lies in transforming scientific research advancements into new medicines, with a proven track record in developing innovative pharmaceuticals from research to regulatory filings and clinical development.

He is internationally recognized for his achievements and leadership in pharmaceutical development and delivery fields.

Mark Tracy's specialties include pharmaceutical development/CMC, research to development (RtoD) transition, drug delivery, nanotechnology, intracellular delivery and targeting, RNAi/RNA, proteins/peptides, polymers, liposomes, collaborations and alliances, technology assessment, program management, team leadership, business planning, and entrepreneurship.

His educational background includes a Ph.D. in Chemistry from Stanford University, an MS in Chemical Engineering from Stanford University, and a BS in Chemical Engineering from the University of Illinois Urbana-Champaign.

Mark Tracy has held key positions such as President at Tracy BioConsulting, LLC, former President at Controlled Release Society, former Senior Director at Alnylam, Inc., and former Director at Alkermes, Inc.